

Review of TA411; Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

Decision

The guidance remains relevant and an update is not needed.

Background

TA411 was published in September 2016 and scheduled to be considered for review in 2019.

Stakeholders were asked whether the guidance is still relevant and whether there is new evidence that would affect the recommendations (see appendix B).

Based on the information received, we found nothing new that affects the existing recommendations. The guidance remains relevant and an update is not needed.

This may change if NICE becomes aware of new evidence that would make it reconsider.

Decision paper sign off

Jennifer Prescott – Programme Director, Planning and Operations

20 May 2020

Contributors to this paper

Project Manager: Charlotte Downing

Appendix A – Information from existing guidance

Original remit

To appraise the clinical and cost effectiveness of necitumumab within its marketing authorisation for untreated advanced, metastatic, squamous non-small-cell lung cancer.

Current guidance

1.1 Necitumumab, in combination with gemcitabine and cisplatin, is not recommended within its marketing authorisation for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.

1.2 This guidance is not intended to affect the position of patients whose treatment with necitumumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

Appendix B – Stakeholders approached for comment

Stakeholders who agree that the guidance should remain unchanged

- British Thoracic Oncology group (BTOG)
- Eli Lilly and Company Limited
- Royal College of Pathologists
- Teva

No response received from

- Accord healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
- Actavis UK (docetaxel, gemcitabine, paclitaxel, vinorelbine)
- All Wales Therapeutics and Toxicology Centre
- Allergan (docetaxel, gemcitabine, paclitaxel, vinorelbine)
- Allied Health Professionals Federation
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- Black Health Agency
- Board of Community Health Councils in Wales
- British Geriatrics Society
- British Institute of Radiology
- British Lung Foundation
- British National Formulary
- British Psychosocial Oncology Society
- British Thoracic Society
- Cancer Black Care
- Cancer Equality
- Cancer Research UK
- Care Quality Commission
- Cochrane Lung Cancer Group
- Department of Health and Social Care

- Department of Health, Social Services and Public Safety for Northern Ireland
- Dr Reddy's Laboratories (docetaxel)
- Fresenius Kabi (paclitaxel)
- Genomics England
- Healthcare Improvement Scotland
- Helen Rollason Cancer Charity
- Hospira UK (carboplatin, docetaxel, gemcitabine, paclitaxel)
- Independent Cancer Patients Voice
- Institute of Cancer Research
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie
- Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine)
- Medicines and Healthcare Products Regulatory Agency
- MRC Clinical Trials Unit
- Muslim Council of Britain
- Mylan (cisplatin, gemcitabine)
- National Association of Primary Care
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- National Lung Cancer Forum for Nurses
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- NHS England and NHS Improvement
- NHS North Staffordshire CCG
- NHS Richmond CCG
- Pierre Fabre (vinorelbine)
- Primary Care Respiratory Society
- Public Health England
- Public Health Wales

- Roy Castle Lung Cancer Foundation
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Sanofi (docetaxel)
- Scottish Medicines Consortium
- Society and College of Radiographers
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sun Pharmaceuticals (carboplatin, gemcitabine)
- Tenovus Cancer Care
- UK Clinical Pharmacy Association
- UK Lung Cancer Coalition
- UK Oncology Nursing Society
- Welsh Government
- Welsh Health Specialised Services Committee
- Wockhardt UK (carboplatin, cisplatin, paclitaxel)